JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB303162

HRP Anti-Cathepsin L/V/K/H antibody [EPR8011]

Be the first to review this product! Submit a review

|

(0 Publication)

Rabbit Recombinant Monoclonal Cathepsin L/MEP antibody - conjugated to HRP.

View Alternative Names

CTSL1, CTSL, Procathepsin L, Cathepsin L1, Major excreted protein, MEP

  • 617 Alexa Fluor® 594

    Alexa Fluor® 594 Anti-Cathepsin L/V/K/H antibody [EPR8011]

  • 578 PE

    PE Anti-Cathepsin L/V/K/H antibody [EPR8011]

  • 660 APC

    APC Anti-Cathepsin L/V/K/H antibody [EPR8011]

  • 519 Alexa Fluor® 488

    Alexa Fluor® 488 Anti-Cathepsin L/V/K/H antibody [EPR8011]

  • 665 Alexa Fluor® 647

    Alexa Fluor® 647 Anti-Cathepsin L/V/K/H antibody [EPR8011]

  • 565 Alexa Fluor® 555

    Alexa Fluor® 555 Anti-Cathepsin L/V/K/H antibody [EPR8011]

  • 603 Alexa Fluor® 568

    Alexa Fluor® 568 Anti-Cathepsin L/V/K/H antibody [EPR8011]

  • 775 Alexa Fluor® 750

    Alexa Fluor® 750 Anti-Cathepsin L/V/K/H antibody [EPR8011]

  • Unconjugated

    Anti-Cathepsin L/V/K/H antibody [EPR8011]

  • Carrier free

    Anti-Cathepsin L/V/K/H antibody [EPR8011] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR8011

Isotype

IgG

Conjugation

HRP

Excitation/Emission
Carrier free

No

Applications

Antibody Labelling, Target Binding Affinity

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

style
left-column

Product details

This conjugated primary antibody is “made to order” and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.

For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.

How are conjugated primary antibodies validated?
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

style
left-column

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.4 Preservative: 0.1% Proclin 300 Solution Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle|Store in the dark
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Cathepsins L V K and H are essential cysteine proteases that serve important functions in protein catabolism. These proteases participate in proteolytic processes by digesting proteins into shorter peptides and amino acids. Cathepsin L also known as CTSL typically has a molecular mass of about 25-35 kDa and is expressed in various tissues such as the liver spleen and placenta. Cathepsin K plays a similar role in bone resorption and is highly expressed in osteoclasts. Cathepsin V and Cathepsin H meanwhile have distinct tissue distributions with cathepsin V often found in the thymus and testis whereas cathepsin H's expression spans across different cell types contributing a vast array of biological functions.
Biological function summary

Cathepsins regulate cellular homeostasis and modulate various physiological processes. These proteases perform their functions within the lysosomal compartment although they can also participate in extracellular matrix remodeling and other non-lysosomal roles. Cathepsin K for example is part of the cathepsin protein family and aids in degrading collagen therefore playing a pivotal role in bone turnover and resorption. Cathepsins can act independently or in some cases are part of larger enzyme complexes enhancing their proteolytic activity to handle different substrates driven by the physiological demand.

Pathways

Cathepsins key in the lysosomal degradation pathway and influence other signaling cascades like the apoptotic pathway. The regulation of these pathways often involves interactions with other proteins such as pro-apoptotic members of the Bcl-2 family facilitating cell death under certain conditions. Cathepsin L contributes to the antigen processing pathway linking it to the immune response. Cathepsin K on the other hand acts closely with structural proteins like collagen in the bone metabolism pathway highlighting its significance in skeletal development and maintenance.

Altered cathepsin activity closely associates with conditions like osteoporosis and cancer. Cathepsin K upregulation can lead to excessive bone degradation seen in osteoporosis while aberrant cathepsin L expression relates to cancer progression and metastasis due to its role in degrading extracellular matrix components facilitating tumor invasion. In osteoporosis interactions with matrix metalloproteinases further enhance bone matrix breakdown exacerbating disease symptoms. In cancer the relationship between cathepsin L and the urokinase-type plasminogen activator system highlights its role in promoting malignancy and suggests potential therapeutic targets.
style
left-column
style
left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:
style
left-column

Target data

Thiol protease important for the overall degradation of proteins in lysosomes (Probable). Plays a critical for normal cellular functions such as general protein turnover, antigen processing and bone remodeling. Involved in the solubilization of cross-linked TG/thyroglobulin and in the subsequent release of thyroid hormone thyroxine (T4) by limited proteolysis of TG/thyroglobulin in the thyroid follicle lumen (By similarity). In neuroendocrine chromaffin cells secretory vesicles, catalyzes the prohormone proenkephalin processing to the active enkephalin peptide neurotransmitter (By similarity). In thymus, regulates CD4(+) T cell positive selection by generating the major histocompatibility complex class II (MHCII) bound peptide ligands presented by cortical thymic epithelial cells. Also mediates invariant chain processing in cortical thymic epithelial cells (By similarity). Major elastin-degrading enzyme at neutral pH. Accumulates as a mature and active enzyme in the extracellular space of antigen presenting cells (APCs) to regulate degradation of the extracellular matrix in the course of inflammation (By similarity). Secreted form generates endostatin from COL18A1 (PubMed : 10716919). Critical for cardiac morphology and function. Plays an important role in hair follicle morphogenesis and cycling, as well as epidermal differentiation (By similarity). Required for maximal stimulation of steroidogenesis by TIMP1 (By similarity).. (Microbial infection) In cells lacking TMPRSS2 expression, facilitates human coronaviruses SARS-CoV and SARS-CoV-2 infections via a slow acid-activated route with the proteolysis of coronavirus spike (S) glycoproteins in lysosome for entry into host cell (PubMed : 16339146, PubMed : 18562523, PubMed : 32142651, PubMed : 32221306, PubMed : 37990007). Proteolysis within lysosomes is sufficient to activate membrane fusion by coronaviruses SARS-CoV and EMC (HCoV-EMC) S as well as Zaire ebolavirus glycoproteins (PubMed : 16081529, PubMed : 18562523, PubMed : 26953343).. Isoform 2. Functions in the regulation of cell cycle progression through proteolytic processing of the CUX1 transcription factor (PubMed : 15099520). Translation initiation at downstream start sites allows the synthesis of isoforms that are devoid of a signal peptide and localize to the nucleus where they cleave the CUX1 transcription factor and modify its DNA binding properties (PubMed : 15099520).
See full target information CTSL

Additional targets

CTSV,CTSK,CTSH
style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB42355

Anti-HIV1 Nef antibody [3D12]

Western blot - Anti-HIV1 Nef antibody [3D12] (AB42355)

  • 4
  • 1
Assay Kits

AB252899

Tyrosinase Activity Assay Kit (Colorimetric)

Functional Studies - Tyrosinase Activity Assay Kit (Colorimetric) (AB252899)

  • 0
  • 0
Primary Antibodies

AB137872

Anti-LEF1 antibody [EPR2029Y]

BOND RX™ Validated|20ul selling size|RabMAb|Recombinant|KO Validated

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-LEF1 antibody [EPR2029Y] (AB137872)

  • 5
  • 3
Primary Antibodies

AB255598

Anti-Granzyme B antibody [EPR22645-206]

BOND RX™ Validated|RabMAb|Recombinant

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Granzyme B antibody [EPR22645-206] (AB255598)

  • 4
  • 3

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com